Scinai Immunotherapeutics Ltd.
SCNI
$1.13
-$0.14-11.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 06/30/2024 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -- | -- | 5.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | 3.19M |
| Total Operating Expenses | -- | -- | -- | -- | 14.62M |
| Operating Income | -- | -- | -- | -- | -14.62M |
| Income Before Tax | -- | -- | -- | -- | -10.91M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | -- | -10.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -- | -10.91M |
| EBIT | -- | -- | -- | -- | -14.62M |
| EBITDA | -- | -- | -- | -- | -14.05M |
| EPS Basic | -- | -- | -- | -- | -125.32K |
| Normalized Basic EPS | -- | -- | -- | -- | -15.44 |
| EPS Diluted | -- | -- | -- | -- | -165.80K |
| Normalized Diluted EPS | -- | -- | -- | -- | -15.44 |
| Average Basic Shares Outstanding | -- | -- | -- | -- | 1.33M |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | 100.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |